Haisco Pharmaceutical Group Co., Ltd (SHE: 002653), a prominent Chinese pharmaceutical company, has announced that its marketing application for HSK21542, a Category 1 drug, has been accepted for review by the National Medical Products Administration (NMPA). The drug is intended for the treatment of moderate to severe itching associated with chronic kidney disease in adult patients undergoing maintenance hemodialysis.
HSK21542 is a selective peripheral Kappa receptor agonist known for its high selectivity and affinity. It works by synergistically regulating potassium and calcium currents through G protein involvement, effectively inhibiting the transmission of itching signals. This mechanism reduces the excitability of dorsal root ganglion and peripheral sensory nerves, leading to a decrease in the release of inflammatory factors and neurotransmitters responsible for itching. Notably, HSK21542 does not cross the blood-brain barrier, allowing it to provide peripheral analgesic and anti-itch effects while avoiding central opioid-related side effects such as hallucinations, addiction, and respiratory depression.
In addition to its application for itching, Haisco is also processing a marketing filing for HSK21542 for use in postoperative analgesia following abdominal surgery, further expanding its therapeutic potential.- Flcube.com
